Upstream & Downstream Processing

Cytiva makes good on China single-use expansion

Plans to triple single-use component production in China through a longstanding partnership with Wego Pharmaceutical are well underway, says Cytiva. Wego Pharmaceutical Co.’s Weihai, China facility makes single-use bioprocessing consumables on behalf of Cytiva after the two firms forged a partnership in November 2018. The site will expand its capacity through plans envisaged last September but announced last week. “Three new manufacturing lines were launched in under ten months with an additional eight new lines planned to launch in Q3…

Advantages of flexible manufacturing in advanced therapies

With rapid market growth and over 1220 ongoing clinical trials, the need for flexible alternatives is higher than ever. To meet this demand, advanced therapeutic developers are utilizing flexible manufacturing and single-use technologies. This is an abridged version of an article first published as part of the BioProcess Insider ebook, entitled: Cell and Gene Therapies — A 2021 Industry Update. To download the full report, click here. Utilizing flexible systems like premanufactured cleanrooms can reduce costs, construction timelines, and time…

Thermo Fisher doubling single-use capacity through $100m Nashville plant

Thermo Fisher will hire 1,400 staff at the facility in Nashville, Tennessee, which is expected to feed biomanufacturing’s continued demand for single-use technologies. Bioprocess vendor Thermo Fisher Scientific unveiled plans yesterday to bolster its manufacturing network for single-use technology (SUT) products through the construction of a facility in Wilson County, Tennessee. “The new site will be Thermo Fisher’s largest designated SUT manufacturing facility and will help more than double Thermo Fisher’s network manufacturing capacity to support its biopharma customers,” a…

Avantor upping its single-use game in $2.9bn Masterflex buy

Avantor is set to acquire Masterflex, a manufacturer of peristaltic pumps and aseptic single-use fluid transfer tech used in upstream, downstream and fill-finish services. The deal, announced yesterday, “strengthens Avantor’s offering across all bioproduction platforms including monoclonal antibodies (mAbs), cell and gene therapy and mRNA, and supports both therapy and vaccine manufacturing including COVID-19,” the firm said in a statement. The $2.9 billion transaction ($2.7 billion after tax benefits) will add Vernon Hills, Illinois-headquartered tech firm Masterflex to the biopharma…

PBS to expand single-use bioreactor tech to feed cell therapy demand

Single-use bioreactor maker PBS Biotech has closed a private $10 million funding round with BroadOak Capital Partners to advance its Vertical-Wheel technology. The funding will be used to expand PBS’ internal operations and capacity, the firm told Bioprocess Insider, to meet the demand and need for its biomanufacturing customers, specifically for cell therapies. Such “investment in manufacturing, engineering and contract services capabilities is required to maintain our rapid growth trajectory in the cell therapy market, we were told. The California-headquartered…

Zymeworks on how to keep immune system at bay when developing bispecifics

BioProcess Insider sat down figuratively with Zymeworks’ chief scientific officer Tony Polverino to talk all things antibody and their solution to challenges that surround bispecific antibody-based cancer therapies.   BioProcess Insider (BI): What are the challenges that surround bispecific antibody-based cancer therapies?  Tony Polverino (TP): I think that the challenges fall into a number of different areas, one being manufacturing, as the ability to bring two different molecules together, or two different binding arms together into the same molecule presents a challenge from an expression and a manufacturing perspective. BI: How have you overcome these issues? …

UK group says 3D printed automated control tech can cut mAb production costs

Automation provides a path to cheaper, faster monoclonal antibody (mAb) production says the UK consortium, which is using 3D printing to develop a tech-independent biomanufacturing control system. The consortium – which includes BiologIC Technologies, Biopharm Services, the UK Center for Process Innovation (CPI), Pall and SCIEX – announced the pact in July, explaining the plan is to develop a prototype strategy and overlay it onto an existing, small scale mAb line. BiologIC Technologies’ role is to use its 3D printing technology to develop…

Polyplus reagent aims to ease CGT manufacturing issues

Polyplus has added a reagent to its existing product line developed specifically to enable large-scale viral vector manufacturing. The French-biotech said the reagent has been developed to complement its existing FectoVir-AAV reagent line. “FectoVIR-AAV is a transfection reagent, hence a key component of upstream manufacturing of viral vectors used for gene therapy,” a spokesperson for Polyplus told BioProcess Insider. “FectoVIR-AAV transports plasmid DNA across the cell membrane. In gene therapy viral vector manufacturing, three plasmids are transfected at the same time…

Merck KGaA highlights MilliporeSigma as ‘star performer’ in Q2

After another record quarter, Germany’s Merck expects a COVID-19 windfall of €1 billion in 2021, the bulk of which coming from its Process Solutions unit. The German biopharma giant reported double-digit growth across all its segments in the second quarter 2021, but highlighted significant contributions from its ‘Big 3’: its Healthcare pipeline, Process Solutions, and Semiconductor Solutions units. The Process Solutions business, which falls under its Life Science business MilliporeSigma and offers biopharmaceutical products and services, pulled in €1.15 billion…

Advanced Instruments buying cell line dev tech firm Solentim

Advanced Instruments will add antibody and cell-based therapy workflow tech through the acquisition of Solentim. “The coming together of Advanced Instruments’ and Solentim’s core technologies, will be a powerful combination in support of clonal cell line development,” Byron Selman, CEO of Advanced Instruments, said. “With Solentim, we are acquiring innovative technologies that will enhance our ability to support customers in these workflows. We are also adding to our technical capabilities with the addition of imaging, advanced AI capabilities and automation…